MXPA05007470A - Metodo para reducir la morbilidad y mortalidad cardiovascular en pacientes prediabeticos y pacientes con diabetes de tipo 2. - Google Patents
Metodo para reducir la morbilidad y mortalidad cardiovascular en pacientes prediabeticos y pacientes con diabetes de tipo 2.Info
- Publication number
- MXPA05007470A MXPA05007470A MXPA05007470A MXPA05007470A MXPA05007470A MX PA05007470 A MXPA05007470 A MX PA05007470A MX PA05007470 A MXPA05007470 A MX PA05007470A MX PA05007470 A MXPA05007470 A MX PA05007470A MX PA05007470 A MXPA05007470 A MX PA05007470A
- Authority
- MX
- Mexico
- Prior art keywords
- patients
- type
- mortality
- prediabetic
- diabetes
- Prior art date
Links
- 206010018429 Glucose tolerance impaired Diseases 0.000 title abstract 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title abstract 3
- 108010092217 Long-Acting Insulin Proteins 0.000 title abstract 2
- 102000016261 Long-Acting Insulin Human genes 0.000 title abstract 2
- 229940100066 Long-acting insulin Drugs 0.000 title abstract 2
- 230000002526 effect on cardiovascular system Effects 0.000 title abstract 2
- 108010057186 Insulin Glargine Proteins 0.000 abstract 1
- COCFEDIXXNGUNL-RFKWWTKHSA-N Insulin glargine Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(=O)NCC(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 COCFEDIXXNGUNL-RFKWWTKHSA-N 0.000 abstract 1
- 229960002869 insulin glargine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43994103P | 2003-01-14 | 2003-01-14 | |
| PCT/US2004/000879 WO2004064862A1 (en) | 2003-01-14 | 2004-01-14 | Long acting insulin for reducing cardiovascular morbidity and mortality in prediabetic patients and patients with type 2 diabetes |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MXPA05007470A true MXPA05007470A (es) | 2005-09-21 |
Family
ID=23746761
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MXPA05007470A MXPA05007470A (es) | 2003-01-14 | 2004-01-14 | Metodo para reducir la morbilidad y mortalidad cardiovascular en pacientes prediabeticos y pacientes con diabetes de tipo 2. |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US7405196B2 (https=) |
| EP (2) | EP1589991A1 (https=) |
| JP (1) | JP5389325B2 (https=) |
| AU (2) | AU2004206829B2 (https=) |
| BR (1) | BRPI0406499A (https=) |
| CA (1) | CA2512820C (https=) |
| CY (1) | CY1118738T1 (https=) |
| DK (1) | DK2596800T3 (https=) |
| ES (1) | ES2604359T3 (https=) |
| GB (1) | GB0309154D0 (https=) |
| HU (1) | HUE031892T2 (https=) |
| IL (3) | IL169697A (https=) |
| MX (1) | MXPA05007470A (https=) |
| PT (1) | PT2596800T (https=) |
| SI (1) | SI2596800T1 (https=) |
| WO (1) | WO2004064862A1 (https=) |
Families Citing this family (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9006175B2 (en) | 1999-06-29 | 2015-04-14 | Mannkind Corporation | Potentiation of glucose elimination |
| US6923175B2 (en) | 2002-03-20 | 2005-08-02 | Mannkind Corporation | Inhalation apparatus |
| DE602004021603D1 (de) * | 2003-07-25 | 2009-07-30 | Conjuchem Biotechnologies Inc | Insulinderivative mit langanhaltender wirkung und verfahren zu deren herstellung |
| ATE486064T1 (de) | 2004-08-20 | 2010-11-15 | Mannkind Corp | Katalyse der diketopiperazinsynthese |
| KR20130066695A (ko) | 2004-08-23 | 2013-06-20 | 맨카인드 코포레이션 | 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염 |
| MX373000B (es) | 2005-09-14 | 2020-05-21 | Mannkind Corp | Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas. |
| EP1986679B1 (en) | 2006-02-22 | 2017-10-25 | MannKind Corporation | A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent |
| CN101827626B (zh) | 2008-06-13 | 2015-03-18 | 曼金德公司 | 干粉吸入器和用于药物输送的系统 |
| US8485180B2 (en) | 2008-06-13 | 2013-07-16 | Mannkind Corporation | Dry powder drug delivery system |
| ES2421385T3 (es) | 2008-06-20 | 2013-09-02 | Mannkind Corp | Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación |
| TWI532497B (zh) | 2008-08-11 | 2016-05-11 | 曼凱公司 | 超快起作用胰島素之用途 |
| CN102256618A (zh) | 2008-10-17 | 2011-11-23 | 赛诺菲-安万特德国有限公司 | 胰岛素和glp-1激动剂的组合 |
| US10437962B2 (en) | 2008-12-23 | 2019-10-08 | Roche Diabetes Care Inc | Status reporting of a structured collection procedure |
| US9918635B2 (en) | 2008-12-23 | 2018-03-20 | Roche Diabetes Care, Inc. | Systems and methods for optimizing insulin dosage |
| US10456036B2 (en) * | 2008-12-23 | 2019-10-29 | Roche Diabetes Care, Inc. | Structured tailoring |
| US8849458B2 (en) * | 2008-12-23 | 2014-09-30 | Roche Diagnostics Operations, Inc. | Collection device with selective display of test results, method and computer program product thereof |
| CN102265280A (zh) * | 2008-12-23 | 2011-11-30 | 霍夫曼-拉罗奇有限公司 | 用于在收集设备上运行的结构化收集过程的实现、执行、数据收集和数据分析的管理方法和系统 |
| US9117015B2 (en) | 2008-12-23 | 2015-08-25 | Roche Diagnostics Operations, Inc. | Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device |
| US20120011125A1 (en) | 2008-12-23 | 2012-01-12 | Roche Diagnostics Operations, Inc. | Management method and system for implementation, execution, data collection, and data analysis of a structured collection procedure which runs on a collection device |
| US8314106B2 (en) | 2008-12-29 | 2012-11-20 | Mannkind Corporation | Substituted diketopiperazine analogs for use as drug delivery agents |
| DK2405963T3 (da) | 2009-03-11 | 2013-12-16 | Mannkind Corp | Apparat, system og fremgangsmåde til at måle modstand i en inhalator |
| KR102584844B1 (ko) | 2009-06-12 | 2023-10-04 | 맨카인드 코포레이션 | 한정된 비표면적을 갖는 디케토피페라진 마이크로입자 |
| PL2451437T3 (pl) | 2009-07-06 | 2017-05-31 | Sanofi-Aventis Deutschland Gmbh | Wodne preparaty insuliny zawierające metioninę |
| CA2778698A1 (en) | 2009-11-03 | 2011-05-12 | Mannkind Corporation | An apparatus and method for simulating inhalation efforts |
| TR201809460T4 (tr) | 2009-11-13 | 2018-07-23 | Sanofi Aventis Deutschland | Bir GLP- 1-agonisti, bir insülin ve metiyonin içeren farmasötik bileşim. |
| NZ599847A (en) | 2009-11-13 | 2013-09-27 | Sanofi Aventis Deutschland | Pharmaceutical composition comprising a glp-1 agonist and methionine |
| AU2011202239C1 (en) | 2010-05-19 | 2017-03-16 | Sanofi | Long-acting formulations of insulins |
| US8532933B2 (en) | 2010-06-18 | 2013-09-10 | Roche Diagnostics Operations, Inc. | Insulin optimization systems and testing methods with adjusted exit criterion accounting for system noise associated with biomarkers |
| CN102985125A (zh) | 2010-06-21 | 2013-03-20 | 曼金德公司 | 干粉药物输送系统和方法 |
| WO2012028172A1 (en) | 2010-08-30 | 2012-03-08 | Sanofi-Aventis Deutschland Gmbh | Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2 |
| US20120173151A1 (en) | 2010-12-29 | 2012-07-05 | Roche Diagnostics Operations, Inc. | Methods of assessing diabetes treatment protocols based on protocol complexity levels and patient proficiency levels |
| SG194034A1 (en) | 2011-04-01 | 2013-11-29 | Mannkind Corp | Blister package for pharmaceutical cartridges |
| US8755938B2 (en) | 2011-05-13 | 2014-06-17 | Roche Diagnostics Operations, Inc. | Systems and methods for handling unacceptable values in structured collection protocols |
| US9821032B2 (en) | 2011-05-13 | 2017-11-21 | Sanofi-Aventis Deutschland Gmbh | Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin |
| US8766803B2 (en) | 2011-05-13 | 2014-07-01 | Roche Diagnostics Operations, Inc. | Dynamic data collection |
| WO2012174472A1 (en) | 2011-06-17 | 2012-12-20 | Mannkind Corporation | High capacity diketopiperazine microparticles |
| AR087693A1 (es) | 2011-08-29 | 2014-04-09 | Sanofi Aventis Deutschland | Combinacion farmaceutica para uso en el control glucemico en pacientes con diabetes de tipo 2 |
| TWI559929B (en) | 2011-09-01 | 2016-12-01 | Sanofi Aventis Deutschland | Pharmaceutical composition for use in the treatment of a neurodegenerative disease |
| MX2014004983A (es) | 2011-10-24 | 2014-09-22 | Mannkid Corp | Metodos y composiciones para tratar dolor. |
| EP2785366A1 (en) * | 2011-12-01 | 2014-10-08 | Sanofi | Insulin glargine versus metformin for the first-line treatment of early type 2 diabetes |
| WO2013144273A1 (en) * | 2012-03-28 | 2013-10-03 | Sanofi | Basal insulin therapy |
| KR102264177B1 (ko) | 2012-07-12 | 2021-06-11 | 맨카인드 코포레이션 | 건조 분말 약물 전달 시스템 및 방법 |
| WO2014066856A1 (en) | 2012-10-26 | 2014-05-01 | Mannkind Corporation | Inhalable influenza vaccine compositions and methods |
| EP3587404B1 (en) | 2013-03-15 | 2022-07-13 | MannKind Corporation | Microcrystalline diketopiperazine compositions, methods for preparation and use thereof |
| EP2983697B1 (en) | 2013-04-03 | 2018-10-31 | Sanofi | Treatment of diabetes mellitus by long acting formulations of insulins |
| MX375448B (es) | 2013-07-18 | 2025-03-06 | Mannkind Corp | Composiciones farmacéuticas en polvo seco estables al calor y métodos. |
| EP3030294B1 (en) | 2013-08-05 | 2020-10-07 | MannKind Corporation | Insufflation apparatus |
| US10307464B2 (en) | 2014-03-28 | 2019-06-04 | Mannkind Corporation | Use of ultrarapid acting insulin |
| WO2016001185A1 (en) * | 2014-07-02 | 2016-01-07 | Novo Nordisk A/S | Dosage regimen for the treatment of diabetes |
| US10561806B2 (en) | 2014-10-02 | 2020-02-18 | Mannkind Corporation | Mouthpiece cover for an inhaler |
| PE20171622A1 (es) | 2014-12-12 | 2017-11-02 | Sanofi Aventis Deutschland | Formulacion de relacion fija de insulina glargina/lixisenatida |
| TWI748945B (zh) | 2015-03-13 | 2021-12-11 | 德商賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患治療 |
| TW201705975A (zh) | 2015-03-18 | 2017-02-16 | 賽諾菲阿凡提斯德意志有限公司 | 第２型糖尿病病患之治療 |
| WO2017108943A1 (en) * | 2015-12-23 | 2017-06-29 | Sanofi-Aventis Deutschland Gmbh | Cardiac metabolic effect of lantus |
| WO2018096164A1 (en) * | 2016-11-28 | 2018-05-31 | Novo Nordisk A/S | Insulin degludec for treating diabetes |
| MA46890A (fr) * | 2016-11-28 | 2021-04-28 | Novo Nordisk As | Insuline degludec pour l'amélioration du contrôle glycémique et la réduction des complications du diabète aigu et à long terme |
| WO2018096162A1 (en) * | 2016-11-28 | 2018-05-31 | Novo Nordisk A/S | Insulin degludec in cardiovascular conditions |
| US11366189B2 (en) * | 2020-09-25 | 2022-06-21 | Uih America, Inc. | Systems and methods for magnetic resonance imaging |
| CN119833121B (zh) * | 2025-01-09 | 2025-10-24 | 南通大学 | 一种糖尿病症状自动检测系统 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5354331A (en) | 1992-07-15 | 1994-10-11 | Schachar Ronald A | Treatment of presbyopia and other eye disorders |
| DE69826286T2 (de) * | 1997-06-27 | 2005-11-24 | Fujisawa Pharmaceutical Co., Ltd. | Derivate mit einem aromatischen ring |
| CO5271699A1 (es) * | 2000-01-24 | 2003-04-30 | Pfizer Prod Inc | Procedimiento para el tratamiento de cardiomiopatia utilizando inhibidores de la glucogeno fosforilasa |
| NZ522036A (en) * | 2000-04-19 | 2004-04-30 | Borody Thomas J | Compositions and therapies for hyperlipidaemia-associated disorders |
| MXPA03003733A (es) * | 2000-10-26 | 2004-10-15 | Fournier Lab Ireland Ltd | Combinacion de fenofibrato y coenzima q10 para el tratamiento de la disfuncion endotelial. |
-
2003
- 2003-04-23 GB GBGB0309154.3A patent/GB0309154D0/en not_active Ceased
-
2004
- 2004-01-14 WO PCT/US2004/000879 patent/WO2004064862A1/en not_active Ceased
- 2004-01-14 EP EP04702167A patent/EP1589991A1/en not_active Withdrawn
- 2004-01-14 EP EP13155801.7A patent/EP2596800B1/en not_active Expired - Lifetime
- 2004-01-14 HU HUE13155801A patent/HUE031892T2/en unknown
- 2004-01-14 US US10/757,201 patent/US7405196B2/en not_active Expired - Lifetime
- 2004-01-14 DK DK13155801.7T patent/DK2596800T3/en active
- 2004-01-14 ES ES13155801.7T patent/ES2604359T3/es not_active Expired - Lifetime
- 2004-01-14 AU AU2004206829A patent/AU2004206829B2/en not_active Expired
- 2004-01-14 PT PT131558017T patent/PT2596800T/pt unknown
- 2004-01-14 CA CA2512820A patent/CA2512820C/en not_active Expired - Lifetime
- 2004-01-14 BR BR0406499-2A patent/BRPI0406499A/pt not_active Application Discontinuation
- 2004-01-14 JP JP2006500944A patent/JP5389325B2/ja not_active Expired - Lifetime
- 2004-01-14 SI SI200432361A patent/SI2596800T1/sl unknown
- 2004-01-14 MX MXPA05007470A patent/MXPA05007470A/es active IP Right Grant
-
2005
- 2005-07-14 IL IL169697A patent/IL169697A/en active IP Right Grant
-
2008
- 2008-06-17 US US12/140,598 patent/US7977310B2/en not_active Expired - Lifetime
-
2009
- 2009-03-22 IL IL197739A patent/IL197739A/en active IP Right Grant
-
2010
- 2010-06-30 AU AU2010202738A patent/AU2010202738B2/en not_active Expired
- 2010-10-06 IL IL208525A patent/IL208525A0/en unknown
-
2011
- 2011-06-03 US US13/152,932 patent/US20110281793A1/en not_active Abandoned
-
2012
- 2012-09-14 US US13/617,341 patent/US8809270B2/en not_active Expired - Lifetime
-
2016
- 2016-11-23 CY CY20161101212T patent/CY1118738T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| PT2596800T (pt) | 2016-12-02 |
| US20080287343A1 (en) | 2008-11-20 |
| IL169697A (en) | 2011-06-30 |
| DK2596800T3 (en) | 2016-12-12 |
| IL197739A (en) | 2017-02-28 |
| US20110281793A1 (en) | 2011-11-17 |
| AU2010202738A1 (en) | 2010-07-22 |
| US8809270B2 (en) | 2014-08-19 |
| CY1118738T1 (el) | 2017-07-12 |
| JP5389325B2 (ja) | 2014-01-15 |
| US20130012433A1 (en) | 2013-01-10 |
| BRPI0406499A (pt) | 2005-12-06 |
| AU2004206829A1 (en) | 2004-08-05 |
| IL197739A0 (en) | 2011-08-01 |
| IL208525A0 (en) | 2010-12-30 |
| WO2004064862A1 (en) | 2004-08-05 |
| EP2596800A1 (en) | 2013-05-29 |
| US7977310B2 (en) | 2011-07-12 |
| US20040229774A1 (en) | 2004-11-18 |
| IL169697A0 (en) | 2007-07-04 |
| GB0309154D0 (en) | 2003-05-28 |
| CA2512820A1 (en) | 2004-08-05 |
| EP2596800B1 (en) | 2016-08-24 |
| SI2596800T1 (sl) | 2017-04-26 |
| AU2004206829B2 (en) | 2010-04-08 |
| EP1589991A1 (en) | 2005-11-02 |
| ES2604359T3 (es) | 2017-03-06 |
| CA2512820C (en) | 2013-06-04 |
| US7405196B2 (en) | 2008-07-29 |
| AU2010202738B2 (en) | 2013-12-05 |
| JP2006515625A (ja) | 2006-06-01 |
| HUE031892T2 (en) | 2017-08-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MXPA05007470A (es) | Metodo para reducir la morbilidad y mortalidad cardiovascular en pacientes prediabeticos y pacientes con diabetes de tipo 2. | |
| TR200001892T2 (tr) | Monomer cinsi ensülin analogları ve bunların kullanımı. | |
| ATE401892T1 (de) | Verwendung von pharmazeutischen zubereitungen enthaltend oxcarbazepin im nüchternzustand | |
| MY145590A (en) | Phenylacetamides and their use as glucokinase modulators | |
| WO2004050115A3 (en) | Combination treatment using exendin-4 and thiazolidinediones | |
| WO2007014094A3 (en) | Method of and system for predicting dose delivery | |
| DK1583571T3 (da) | Medicindispenseringsindretning for insulin | |
| IL198783A0 (en) | Erythropoietin ameliorates chemotherapy-induced toxicity in vivo | |
| BR0308904A (pt) | Método de tratamento de gastroparesia, e, uso de um composto de glp-1 | |
| MX2008004734A (es) | Composicion rica en leucina. | |
| AU2003252182A8 (en) | Therapeutic treatment for the metabolic syndrome and type 2 diabetes | |
| TW200511999A (en) | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone | |
| GB0606001D0 (en) | Combination Of Cicletanine And An Oral Antidiabetic And/Or Blood Lipid-Lowering Agent For Treating Diabetes And Metabolic Syndrome | |
| BR0108261A (pt) | Uso de mirtazapina, método de tratamento de um distúrbio do sono em um indivìduo, e, kit para paciente para o tratamento de distúrbios do sono | |
| MY138246A (en) | Treatment of diabetes with thiazolidione and sulphonylurea. | |
| GB0323979D0 (en) | Therapeutic applications for c-peptide | |
| NZ514911A (en) | Use of N-acetylcysteine for the preparation of a medicament suitable for the intravenous administration to prevent oxidative stress in dialysed patients | |
| GB0128071D0 (en) | Medicament | |
| EP1602374A4 (en) | MEANS FOR TREATMENT OF MEDICAMENT / SUBSTANCE DEPENDENCE | |
| Kieffer et al. | Glucagon and glucagon-like peptide production and degradation | |
| TW200509922A (en) | Methods of therapeutic treatment using amounts of retinoid components | |
| AP2000001787A0 (en) | Use of thiazolidinediones for the treatment of hyperglycaemia. | |
| DE60120371D1 (de) | Verwendung von wachstumshormon in niederen dosen | |
| GB0214142D0 (en) | Blood glucose level monitor and insulin administration device | |
| MD1780G2 (ro) | Metodă de tratament al pacienţilor cu ciroze hepatice |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |